Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer

Annals of Oncology

Volumn 12, Issue 2, 2001, Pages 183-186

  Penz, M ^a   Kornek, G V ^a   Raderer, M ^a   Ulrich Pur, H ^a   Fiebiger, W ^a   Lenauer, A ^b   Depisch, D ^b   Krauss, G ^c   Schneeweiss, B ^a   Scheithauer, W ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b General Hospital Wiener Neustadt   (Austria)

^c Stockerau Hospital   (Austria)

Author keywords

Biliary tract cancer; Chemotherapy; Gemcitabine

Indexed keywords

GEMCITABINE; ONDANSETRON;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BILIARY TRACT CANCER; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; INFECTION; LEUKOPENIA; MALE; METASTASIS; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; SKIN TOXICITY; THROMBOCYTOPENIA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BILIARY TRACT NEOPLASMS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0035108122     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008352123009     Document Type: Article

References (22)

1. Neoplasms of the hepatobiliary system
2. Biliary tract cancers
3. The role of chemotherapy and radiation in the management of biliary cancer: A review of the literature
4. Gemcitabine: Status of preclinical studies and perspectives for the future clinical applications of this novel nucleoside analog
5. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
6. Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: A case report
7. A phase II trial of gemcitabine in gallbladder and biliary tract carcinomas
8. Gemcitabine for the treatment of advanced biliary tract carcinomas: Evaluation of two different dose regimens
9. Gemcitabine (GEM): An active drug in advanced gallbladder cancer (AGC)
10. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors
11. Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine
12. In vitro Evaluierung potentiell effektiver Gemcitabine-Kombinationstherapien beim exokrinen Pankreaskarzinom
13. Phase I study of gemcitabine given weekly as short infusion
14. Maximum-tolerated dose defined for single agent gemcitabine: A phase I dose-escalation study in chemotherapy-naïve patients with advanced non-small-cell lung cancer
15. A phase II trial of biweekly high-dose gemcitabine for patients with metastatic pancreatic adenocarcinoma
16. The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent
17. Approximate confidence intervals for probabilities of survival and quantiles in life-table analysis
18. Non-parametric estimation from incomplete observation
19. A phase I trial of gemcitabine (LY 188011) administered intravenously every two weeks
20. Phase I study of gemcitabine (difluorodeoxycytidine); dFdC; LY 188011) administered in a two-weekly schedule
21. Oral capecitabine (xeloda) for the treatment of hepatobiliary carcinoma, cholangio-carcinoma, and gallbladder cancer